Sonia Cajigal1, Karen E Wells2, Edward L Peterson2, Brian K Ahmedani3, James J Yang4, Rajesh Kumar5, Esteban G Burchard6, L Keoki Williams7. 1. Department of Internal Medicine, Henry Ford Health System, Detroit, Mich. 2. Department of Public Health Sciences, Henry Ford Health System, Detroit, Mich. 3. Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Mich. 4. School of Nursing, University of Michigan, Ann Arbor, Mich. 5. Department of Pediatrics, the Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Ill. 6. Department of Bioengineering & Therapeutic Sciences, University of California San Francisco, San Francisco, Calif; Department of Medicine, University of California San Francisco, San Francisco, Calif. 7. Department of Internal Medicine, Henry Ford Health System, Detroit, Mich; Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Mich. Electronic address: kwillia5@hfhs.org.
Abstract
BACKGROUND: Current US guidelines recommend the Asthma Control Test (ACT) for assessing disease control and selecting treatment. OBJECTIVE: The goal of this study was to prospectively assess the ACT and its component questions for their utility in predicting the risk of severe asthma exacerbations. METHODS: Individuals were participants in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity, and those included in the current analysis had the following characteristics: age 18 years or more, physician-diagnosed asthma, and longitudinal care received at a large health system in southeastern Michigan. Study participants underwent a baseline evaluation, which included answering the ACT. A severe asthma exacerbation was defined as one requiring oral steroids, an emergency department visit, or inpatient admission. Receiver-operator characteristic curves were used to measure and compare the predictive utility of the ACT and its component questions for severe asthma exacerbations. RESULTS: Of 1180 participants, 354 (30.0%) experienced a severe asthma exacerbation within 6 months of their baseline evaluation. When compared with the individual questions that composed the ACT, the composite score was significantly better at predicting severe exacerbations with 1 exception; the composite ACT score and the question assessing rescue medication use were not significantly different (P = .580). Pharmacy-based records of metered-dose inhaler short-acting beta-agonist use and asthma severity were also not significantly different from the composite ACT score. CONCLUSIONS: Our study demonstrates that although the ACT is modestly predictive for exacerbations, the composite score may not be superior to assessing rescue medication use alone for predicting the risk of severe asthma exacerbations.
BACKGROUND: Current US guidelines recommend the Asthma Control Test (ACT) for assessing disease control and selecting treatment. OBJECTIVE: The goal of this study was to prospectively assess the ACT and its component questions for their utility in predicting the risk of severe asthma exacerbations. METHODS: Individuals were participants in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity, and those included in the current analysis had the following characteristics: age 18 years or more, physician-diagnosed asthma, and longitudinal care received at a large health system in southeastern Michigan. Study participants underwent a baseline evaluation, which included answering the ACT. A severe asthma exacerbation was defined as one requiring oral steroids, an emergency department visit, or inpatient admission. Receiver-operator characteristic curves were used to measure and compare the predictive utility of the ACT and its component questions for severe asthma exacerbations. RESULTS: Of 1180 participants, 354 (30.0%) experienced a severe asthma exacerbation within 6 months of their baseline evaluation. When compared with the individual questions that composed the ACT, the composite score was significantly better at predicting severe exacerbations with 1 exception; the composite ACT score and the question assessing rescue medication use were not significantly different (P = .580). Pharmacy-based records of metered-dose inhaler short-acting beta-agonist use and asthma severity were also not significantly different from the composite ACT score. CONCLUSIONS: Our study demonstrates that although the ACT is modestly predictive for exacerbations, the composite score may not be superior to assessing rescue medication use alone for predicting the risk of severe asthma exacerbations.
Authors: Robert S Zeiger; Ashley Yegin; F Estelle R Simons; Tmirah Haselkorn; Lawrence Rasouliyan; Stanley J Szefler; Bradley E Chipps Journal: Ann Allergy Asthma Immunol Date: 2012-02 Impact factor: 6.347
Authors: Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy Journal: Am J Respir Crit Care Med Date: 2009-05-29 Impact factor: 21.405
Authors: Gail M Gauvreau; Paul M O'Byrne; Louis-Philippe Boulet; Ying Wang; Donald Cockcroft; Jeannette Bigler; J Mark FitzGerald; Michael Boedigheimer; Beth E Davis; Clapton Dias; Kevin S Gorski; Lynn Smith; Edgar Bautista; Michael R Comeau; Richard Leigh; Jane R Parnes Journal: N Engl J Med Date: 2014-05-20 Impact factor: 91.245
Authors: Chun E Jia; Hong Ping Zhang; Yan Lv; Rui Liang; Yun Qiu Jiang; Heather Powell; Juan Juan Fu; Lei Wang; Peter Gerard Gibson; Gang Wang Journal: J Allergy Clin Immunol Date: 2012-10-08 Impact factor: 10.793
Authors: Albert M Levin; Yun Wang; Karen E Wells; Badri Padhukasahasram; James J Yang; Esteban G Burchard; L Keoki Williams Journal: Am J Respir Crit Care Med Date: 2014-08-01 Impact factor: 21.405
Authors: Jennifer A Rumpel; Brian K Ahmedani; Edward L Peterson; Karen E Wells; Mao Yang; Albert M Levin; James J Yang; Rajesh Kumar; Esteban González Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2012-10-12 Impact factor: 10.793
Authors: Fanny W S Ko; Ting-Fan Leung; David S C Hui; Hong-yin Chu; Gary W K Wong; Eric Wong; Alvin H M Tung; Christopher K W Lai Journal: Respirology Date: 2009-03-25 Impact factor: 6.424
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Nicole M Wagner; Debra P Ritzwoller; Marsha A Raebel; Glenn K Goodrich; Peter J Cvietusa; Diane K King; Jo Ann Shoup; Bruce G Bender Journal: Transl Behav Med Date: 2021-04-07 Impact factor: 3.046
Authors: Maxwell P Cocco; Evan White; Shujie Xiao; Donglei Hu; Angel Mak; Patrick Sleiman; Mao Yang; Kevin R Bobbitt; Hongsheng Gui; Albert M Levin; Samantha Hochstadt; Kyle Whitehouse; Dean Rynkowski; Andrea J Barczak; Gonçalo Abecasis; Thomas W Blackwell; Hyun Min Kang; Deborah A Nickerson; Soren Germer; Jun Ding; David E Lanfear; Frank Gilliland; W James Gauderman; Rajesh Kumar; David J Erle; Fernando Martinez; Hakon Hakonarson; Esteban G Burchard; L Keoki Williams Journal: PLoS One Date: 2020-11-25 Impact factor: 3.240
Authors: Paolo Solidoro; Stefania Nicola; Irene Ridolfi; Giorgio Walter Canonica; Francesco Blasi; Pierluigi Paggiaro; Enrico Heffler; Diego Bagnasco; Filippo Patrucco; Fulvia Ribolla; Caterina Bucca; Giovanni Rolla; Carlo Albera; Luisa Brussino Journal: Biomedicines Date: 2022-01-18
Authors: Bas C P van Dijk; Henrik Svedsater; Andreas Heddini; Linda Nelsen; Janita S Balradj; Cathelijne Alleman Journal: BMC Pulm Med Date: 2020-04-03 Impact factor: 3.317